Contrasting Omnicell (NASDAQ:OMCL) & Coloplast A/S (OTCMKTS:CLPBY)

Omnicell (NASDAQ:OMCL) and Coloplast A/S (OTCMKTS:CLPBY) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.

Profitability

This table compares Omnicell and Coloplast A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Omnicell	3.59%	5.69%	3.61%
Coloplast A/S	10.57%	42.25%	11.87%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Omnicell and Coloplast A/S, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0	2	7	1	2.90
Coloplast A/S	1	1	0	2	2.75

Omnicell presently has a consensus target price of $57.86, suggesting a potential upside of 64.93%. Given Omnicell’s stronger consensus rating and higher possible upside, equities analysts clearly believe Omnicell is more favorable than Coloplast A/S.

Earnings and Valuation

This table compares Omnicell and Coloplast A/S”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18 billion	1.36	$2.05 million	$0.96	36.54
Coloplast A/S	$4.50 billion	3.76	$478.04 million	$0.21	35.79

Coloplast A/S has higher revenue and earnings than Omnicell. Coloplast A/S is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Omnicell has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Coloplast A/S has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500.

Institutional and Insider Ownership

97.7% of Omnicell shares are held by institutional investors. 2.9% of Omnicell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Omnicell beats Coloplast A/S on 8 of the 15 factors compared between the two stocks.

About Omnicell

Omnicell, Inc. develops medication-management solutions for healthcare providers. Its products and services are designed to help manage medication storage, dispensing, inventory and workflows across healthcare settings. The company offers automated dispensing cabinets for patient-care areas, automation systems for central pharmacies, and software and analytics that support medication management. Its solutions serve hospitals, health systems, pharmacies and other care providers, including long-term and post-acute care organizations.

About Coloplast A/S

Coloplast A/S is a Danish medical device company that develops and markets products and services for people with intimate health care needs. Its main business areas include ostomy care, continence care, wound and skin care, and urology care. Its products include ostomy bags and accessories, catheters and other continence products, wound dressings, and devices used in urological procedures. Coloplast also provides voice and respiratory care products, including solutions for people who have had a laryngectomy.